Phase I Study to Evaluate the Tolerability, Pharmacokinetics, Immunogenicity, Safety of Dose Escalation and Preliminary Efficacy of GR1401 in Patients with Advanced Solid Tumors

ABSTRACT: Interventions: Case series:GR1401 monoclonal antibody Primary outcome(s): Maximum tolerated dose;Dose limiting toxicity;Safety assessment Study Design: Case series

DISEASE(S): Colorectal Cancer, Non-small Cell Lung Cancer, Head And Neck Cancer, Esophageal Cancer, Etc

PROVIDER: 2668543 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR